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Abstract
Background: The transient global cerebral hypoperfusion/reperfusion achieved by induction of Bilateral Common
Carotid Artery Occlusion followed by Reperfusion (BCCAO/R) may trigger a physiological response in an attempt to
preserve tissue and function integrity. There are several candidate molecules among which the endocannabinoid
system (ECS) and/or peroxisome-proliferator activated receptor-alpha (PPAR-alpha) may play a role in modulating
oxidative stress and inflammation. The aims of the present study are to evaluate whether the ECS, the enzyme
cyclooxygenase-2 (COX-2) and PPAR-alpha are involved during BCCAO/R in rat brain, and to identify possible
markers of the ongoing BCCAO/R-induced challenge in plasma.
Methods: Adult Wistar rats underwent BCCAO/R with 30 min hypoperfusion followed by 60 min reperfusion. The
frontal and temporal-occipital cortices and plasma were analyzed by high performance liquid chromatography-
mass spectrometry (HPLC-MS) to determine concentrations of endocannabinoids (eCBs) and related molecules
behaving as ligands of PPAR-alpha, and of oxidative-stress markers such as lipoperoxides, while Western Blot and
immunohistochemistry were used to study protein expression of cannabinoid receptors, COX-2 and PPAR-alpha.
Unpaired Student’s t-test was used to evaluate statistical differences between groups.
Results: The acute BCCAO/R procedure is followed by increased brain tissue levels of the eCBs 2-arachidonoylglycerol
and anandamide, palmitoylethanolamide, an avid ligand of PPAR-alpha, lipoperoxides, type 1 (CB1) and type 2 (CB2)
cannabinoid receptors, and COX-2, and decreased brain tissue concentrations of docosahexaenoic acid (DHA), one of
the major targets of lipid peroxidation. In plasma, increased levels of anandamide and lipoperoxides were observed.
Conclusions: The BCCAO/R stimulated early molecular changes that can be easily traced in brain tissue and plasma,
and that are indicative of the tissue physiological response to the reperfusion-induced oxidative stress and
inflammation. The observed variations suggest that the positive modulation of the ECS and the increase of
proinflammatory substances are directly correlated events. Increase of plasmatic levels of anandamide and
lipoperoxides further suggests that dysregulation of these molecules may be taken as an indicator of an
ongoing hypoperfusion/reperfusion challenge.
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Background
The transient Bilateral Common Carotid Artery Occlusion
followed by Reperfusion (BCCAO/R) is a model of transi-
ent global hypoperfusion [1]. This model does not lead to
an authentic ischemic insult in the rodent brain due to the
presence of efficient collateral systems, which allow for a
cerebral blood flow compensation within a few minutes
[2]. However, it has been recently shown that, in the rat,
the cerebral transient hypoperfusion followed by reperfu-
sion, such as that induced by the BCCAO/R, causes de-
tectable and consistent tissue changes such as a decrease
of docosahexaenoic acid (DHA), one of the most abun-
dant polyunsaturated fatty acid in neuronal membrane
phospholipids, an increase of the cyclooxygenase-2
(COX-2) [3] and significant microvascular alterations [4].
The endocannabinoids (eCBs) are endogenous lipid
mediators involved in a wide variety of biological
processes. The most frequently studied eCBs are N-
arachidonoyl-ethanolamide (AEA, anandamide), belong-
ing to the superfamily of N-acylethanolamides (NAEs),
and 2-arachidonoyl-glycerol (2-AG). AEA and 2-AG are
not stored in vesicles but they are synthesized ‘on demand’
and released from plasmatic membranes immediately after
their production when cells are challenged with poten-
tially harmful stimuli [5–7]. Accumulating data show that
eCBs, with their signaling-mediating receptors, and en-
zymes involved in their synthesis and degradation, consti-
tute an extensive system with relative basic levels of each
component that is modulated by different and concurring
molecular mechanisms [8, 9]. Growing evidence supports
a general role for eCBs and congeners in the preservation
of metabolic homeostasis and responsivity of the brain to
stress, and indicate that they are involved in inflammation
and act as endogenous neuroprotectants in cerebral ische-
mia [5, 9–18]. As for the likely involvement of eCB in
neuroinflammation, it has been shown that 2-AG and
AEA are substrates for COX-2 [19] and it is relevant that
the eCB neuroprotective activity may be mediated by
preventing excessive expression of COX-2 [11, 20, 21].
Conversely, COX-2 is a key regulator of eCB signalling
[22]. Moreover, it has been shown that the peroxisome-
proliferator activated receptor (PPAR)-alpha mediates the
anti-inflammatory effects of the non-cannabinoid pal-
mitoylethanolamide (PEA) that behaves as one of its
endogenous ligands [23]. Though the role of eCB
system in neuroprotection is somewhat controversial,
data on focal cerebral ischemia followed by reperfusion
show that i) intraperitoneally administered PEA and
AEA reduce the size of infarcted tissue [7], ii) both
pharmacological blockade [24] and genetic deletion of
CB1 receptor reduce the infarct volume and improve
neurological function [25], and iii) CB2 activation
attenuates the cerebral ischemia/reperfusion-induced
microcirculatory dysfunction [13].
In this study, we investigated whether the eCB system
may be directly correlated to the oxidative events trig-
gered by the BCCAO/R-induced transient global hypo-
perfusion in rat brain, and we chose to examine the
forebrain areas that are directly and selectively reached
by the internal carotid artery branches. With this aim,
we examined, prior to and after induction of BCCAO/R,
cerebral tissue and plasmatic concentrations of eCBs
and of oxidative stress markers such as polyunsaturated
fatty acid (PUFA) hydroperoxides. Parallel immunochemi-
cal analyses, carried out by means of Western Blot and
immunohistochemistry, investigated possible BCCAO/
R-induced changes in the occurrence and tissue distribu-
tion of CB1 and CB2 receptors, COX-2, and the transcrip-
tion factor peroxisome-proliferator activated receptor
(PPAR)-alpha. Results are discussed in view of the possible
use of eCBs and lipoperoxides as markers of an ongoing
transient cerebral global hypoperfusion.
Methods
Experimental procedure
Animals and keeping
For 1 week before the start of the experiment, fifty six
adult male Wistar rats (Harlan-Italy, Udine, Italy), weigh-
ing 210 ± 20 g (mean ± SD) were housed under controlled
temperature (21 ± 2 °C), relative humidity (60 ± 5%) and
artificial 12 h light/dark cycle, avoiding all stressful stimuli.
Animal handling and care throughout the experimental
procedures met with national (Legislative Decree n. 26,
04/04/2014) and international (Directive 2010/63/EU in
Europe) laws and policies. The experimental protocols
were carried out in compliance with the guidelines of the
Animal Ethics Committee of the University of Cagliari.
Standard laboratory food (A04, Safe, Augy, France) and
water were freely available ad libitum.
According to the optimum standard for the evaluation
of lipids in tissue and plasma [6, 26], animals received
no food for 12 h before surgery. Rats were randomly
assigned to two groups (n = 12/group): one group was
submitted to BCCAO and reperfused (BCCAO/R) and
one group was sham-operated. Surgery was performed
in all cases between 13:00 and 16:30 p.m..
Surgery
Surgical procedure for induction of BCCAO/R was
adapted from the method of Iwasaki et al. [27] and per-
formed in all cases between 13:00 and 16:30 p.m.. Rats
were anesthetized with intraperitoneal administration of
Equitesin (4.2% w/v chloral hydrate, 2.12% w/v MgSO4,
16.2% w/w pentobarbital, 39.6% w/w propylene glycol,
and 10% w/w ethanol in sterile distilled H2O) (0.5 ml/
100 g bodyweight). After a midline cervical incision and
blunt dissection of muscles, the common carotid arteries
(CCA) were exposed while leaving the vagus nerve
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intact. Cerebral blood flow reduction was produced by
placement of two atraumatic microvascular clips for
30 min on CCA. The reperfusion period was achieved
by removing the clips and restoring blood flow through
the stenosed vessels for 60 min. The control animals,
used to determine the effects of anaesthesia and surgi-
cal manipulation of the results, were represented by
sham-operated rats that underwent surgery without
CCA occlusion.
Sampling
At the end of the procedure, brain samples were collected
either as fresh tissue for lipid analysis and Western Blot
or after transcardial perfusion fixation with ice cold 4%
formaldehyde in 0.1 M phosphate buffer (PB), pH 7.4
for immunohistochemistry. The frontal cortex was rap-
idly dissected out by a transverse cut made at the level
of the optic chiasm, at the approximate bregma level of
−1.0 mm [28], and frozen at −80 °C until HPLC or
Western Blot analysis. Temporal-occipital cortex, dis-
sected out by a transverse cut at the approximate
bregma level of −4.5 mm, was also sampled as a control
cortical area not irrorated by the internal carotid artery
branches. Blood was quickly collected from the trunk
of killed animals into heparinised tubes and centrifuged
at 1500 g for 10 min at −8 °C. The resulting plasma
was frozen at −20 °C until assayed for lipids. Immuno-
histochemistry was used to determine the tissue distri-
bution and cellular localization of the same markers
used for the Western Blot analysis. Perfused brains
were dissected out and then rinsed overnight in
0.1 M PB, pH 7.3, containing 20% sucrose. After su-
crose infiltration, samples were embedded in Optimal
Cutting Temperature (OCT) medium for cryostat sec-
tioning. For each assay, the investigator was blind with
respect to the experimental condition of the rats.
Endocannabinoid and congener quantifications
Frozen tissues were homogenized and extracted with
50 mM chloroform/methanol/Tris–HCl, pH 7.5 (2:1:1, v/v),
containing internal deuterated standards for anandamide
(AEA), 2-arachidonoyl-monoacylglycerol (2-AG), palmitoyl-
ethanolamide (PEA) and oleoylethanolamide (OEA) quantifi-
cation by isotope dilution ([2H]8 AEA, [2H]5 2-AG, [2H]4
PEA, [2H]4 OEA; Cayman Chemical, Ann Arbor, MI, USA).
AEA, 2-AG, PEA, and OEA were quantified by liquid chro-
matography–atmospheric pressure chemical ionization–mass
spectrometry [1100 HPLC system (Agilent Technologies,
Santa Clara, CA, USA) equipped with MS Detector
6110 single quadrupole] and using selected ion moni-
toring at M1 values for the four compounds and their
deuterated homologs, as described previously [26].
Concentrations (nmoles/g; nmoles/ml) are shown as
histograms in Fig. 1.
Tissue fatty acid quantifications
Total lipids were extracted from different brain areas
using chloroform/methanol 2:1 (v/v). Aliquots were
mildly saponified as previously described [29] in order to
obtain free fatty acids for high-performance liquid chro-
matography (HPLC) analysis. Separation of fatty acids
was carried out with an Agilent 1100 HPLC system (Agi-
lent Technologies) equipped with a diode array detector
as previously reported [6]. Concentrations (nmoles/g;
nmoles/ml) are shown as histograms in Fig. 1.
Western blot
Tissue homogenates were prepared in a 2% solution of
sodium dodecyl sulfate (SDS) containing a cocktail of
protease inhibitors (cOmplete, Mini Protease Inhibitor
Cocktail Tablets, Roche, Basel, Switzerland). Protein
concentrations were determined using the Lowry method
of protein assay [30] with bovine serum albumin as stand-
ard. Proteins for each tissue homogenate (40 μg), diluted
3:1 in 4× loading buffer (NuPAGE LDS Sample Buffer 4×,
Novex by Life Technologies, Carlsbad, CA, USA), were
heated to 95 °C for 10 min and separated by SDS-
polyacrilamide gel electrophoresis (SDS-PAGE) using
precast polyacrylamide gradient gel (NuPAGE 4–12% Bis-
Tris Gel Midi, Novex by Life Technologies) in the XCell4
Sure Lock™ Midi-Cell chamber (Life Technologies).
Internal mw standards (Precision Plus Protein™ Wes-
ternC™ Standards, Bio-Rad, Hercules, CA, USA) were run
in parallel. Two gels at a time were run for Coomassie
staining and immunoblotting, respectively. Proteins for
immunoblotting were electrophoretically transferred on a
polyvinylidene fluoride membrane (Amersham Hybond™-
P, GE Healthcare, Little Chalfont, United Kingdom) using
the Criterion™ Blotter (Bio-Rad). Blots were blocked by
immersion in 20 mM Tris base and 137 mM sodium
chloride (TBS) containing 5% milk powder and 0.1%
Tween 20 (TBS-T), for 60 min at room temperature and
incubated overnight at 4 °C with rabbit polyclonal antisera
directed against CB1 receptor (Synaptic System, Göttingen,
Germany), diluted 1:500, CB2 receptor (MyBioSource, San
Diego, CA, USA), diluted 1:1000, COX-2 (residues 570–
598) (Cayman Chem.), diluted 1:200, and PPAR-α (Thermo
Scientific, Waltham, MA, USA), diluted 1:1000, in TBS
containing 5% milk powder and 0.02% sodium azide, were
used as primary antisera. After TBS-T rinse, blots were in-
cubated for 60 min, at room temperature, with peroxidase-
conjugated goat anti-rabbit serum (Sigma Aldrich, Saint
Louis, MO, USA), diluted 1:10,000 in TBS/T. Loading
controls were obtained by stripping and immunostaining
the membranes with a mouse monoclonal antibody against
the housekeeping protein glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (EMD Millipore, Darmstadt,
Germany), diluted 1:1000, as primary antiserum, and a
peroxidase-conjugated goat anti-mouse serum (EMD
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Millipore), diluted 1:5000, as secondary antiserum. In
order to control for non specific staining, blots were
stripped and incubated with the relevant secondary
antiserum. After TBS-T rinse, protein bands were
visualized using the ECL chemiluminescent system
according to the protocol provided by the company
(GE Healthcare), under ImageQuant LAS 4000.
Approximate molecular weight (mw) and relative
optical density (O.D.) of immunolabelled protein
bands were evaluated by a “blind” examiner, and were
quantified by comparing the position of relevant
bands on the digital images with those of the GAPDH
bands, respectively. The ratio of the intensity of
COX-2- and PPAR-α-positive bands to the intensity
Fig. 1 Endocannabinoids and fatty acid profile in frontal cortex and plasma. High performance liquid chromatography (HPLC) analysis of frontal
cortex (a−f) and plasma (g, h) of sham-operated and bilateral common carotid artery occlusion followed by reperfusion (BCCAO/R) rats. N-arachidonoyl-
ethanolamide (AEA) (a, e), 2-arachidonoyl-glycerol (2-AG) (b), palmitoylethanolamide (PEA) (c), docosahexaenoic acid (DHA) (e) and lipoperoxides (f, h)
concentrations are reported as mean values of 12 sham-operated and 12 BCCAO/R rats. Error bars depict S.D.. Unpaired Student’s t test: *p< 0.05
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of GAPDH-positive ones was used to compare rela-
tive expression levels of these proteins following
BCCAO/R procedure. O.D. was quantified by ImageJ
(http://imagej.nih.gov/ij/). Concentrations (nmoles/g;
nmoles/ml) are shown as histograms in Fig. 2.
Immunohistochemistry
The avidin–biotin–peroxidase complex (ABC) and the
indirect immunofluorescence techniques were used to
process cryostat semiconsecutive sections (16 μm thick),
collected on chrome alum-gelatin coated slides. Coronal
Fig. 2 Western Blot analysis. Cannabinoid receptors CB1 (a, b) and CB2 (c, d), cyclooxygenase-2 (COX-2) (e, f) and peroxisome-proliferator
activated receptor-alpha (PPAR-alpha) (g, h) in the frontal cortex of sham and bilateral common carotid artery occlusion followed by reperfusion
(BCCAO/R) rats. b, d, f, h: densitometric analysis of the band gray levels expressed as a percentage of the optical density (O.D.) ratio of
immunostained bands to those of GAPDH. Data are reported as mean values of 12 sham-operated and 12 BCCAO/R rats. Error bars depict
S.D. Unpaired Student’s t test: *p < 0.05
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serial sections at + 4.70 to - 1.70 mm and at - 3.5 to -
8.0 mm Bregma levels, respectively, were used to focus
the observations on the frontal and temporal-occipital
cortex [28]. For the ABC, the endogenous peroxidase
activity was blocked with 0.1% phenylhydrazine in phos-
phate buffered saline (PBS) containing 0.2% Triton X-100
(PBS/T), followed by incubation with 20% of either
normal goat or normal horse serum (Vector, Burlingame,
CA, USA) for 1 h at RT. For ABC, the primary antibodies
were rabbit polyclonal antibody against CB1 (Synaptic
System), diluted 1:1000 and COX-2 (Cayman Chem.),
diluted 1:300. For immunofluorescence, the primary anti-
bodies were goat polyclonal antiserum against COX-2
(SantaCruz Biotechnology), diluted 1:100, mouse mono-
clonal antibody against Iba1 (WAKO), diluted 1:1000,
rabbit polyclonal antiserum against Glial Fibrillary Acidic
Protein (GFAP) (DAKO), diluted 1:1000. Incubations with
primary antiserum were carried out overnight at 4 °C.
Biotin-conjugated goat anti-rabbit serum (Vector, Burlin-
game, CA, USA), diluted 1:400, was used as secondary
antiserum in the ABC method; Alexa Fluor 488 or 594
donkey anti-goat, anti-mouse and anti-rabbit sera (Invitro-
gen, Eugene, OR, USA), diluted 1:500, were used as sec-
ondary antiserum in the immunofluorescence technique.
The ABC reaction product was revealed with a biotin-
conjugated goat anti-rabbit serum (Vector, Burlingame,
CA, USA), diluted 1:400, as secondary antiserum. The
ABC (BioSpa Div. Milan, Italy), diluted 1:250, followed by
a solution of 0.1 M PB, pH 7.3, containing 0.05% 3,3’-di-
aminobenzidine (Sigma Aldrich), 0.01% hydrogen perox-
ide and 0.04% nickel ammonium sulfate were used to
reveal the reaction product. Incubations with secondary
antiserum and ABC lasted 60 min and were performed at
RT. Negative control preparations were obtained by incu-
bating tissue sections in parallel with either PBS-T alone
or with the relevant primary antiserum preabsorbed with
an excess of the corresponding peptide antigen. Slides
were observed by the same examiner, who was “blind”
with respect to the animals’ treatment, with an Olympus
BX61 microscope, equipped with epifluorescence illumin-
ation, and digital images (Figs. 4, 5) were captured with a
Leica DF 450C camera.
Statistical analysis
Data from the two experimental groups, sham-operated
animals and the BCCAO/R ones, are depicted in the
figures as mean ± standard deviation (S.D.) and statis-
tical differences were determined by unpaired Student’s
t-test.
Results
eCB and fatty acid profiles in brain tissue
In the frontal cortex AEA, 2-AG, and PEA were found
significantly increased in BCCAO/R rats as compared to
the sham-operated ones (p < 0.05) by 41, 51 and 37%, re-
spectively (Fig. 1a–c), while DHA decreased by about 7%
(p < 0.001) (Fig. 1d), and lipoperoxides, considered as a
molecular marker of oxidative stress, increased by 57%
(p < 0.05) (Fig. 1e). No statistically significant changes
were observed in the temporal-occipital cortex (data
not shown).
eCB and fatty acid profiles in plasma
In BCCAO/R rats, analysis of eCBs and congeners re-
vealed that levels of AEA increased significantly by
about 38% compared to sham rats (p < 0.05) (Fig. 1f ),
whereas no change was observed in 2-AG, PEA, and
OEA levels. A strong increase of lipoperoxides could
also be detected (52%; p < 0.05) (Fig. 1g). No statistically
significant changes were observed in the temporal-
occipital cortex (data not shown).
Western blot
After the BCCAO/R, protein changes were detected only
in the frontal cortex homogenates, whereas the
temporal-occipital cortex appeared unaffected. Thus, the
relative levels of the CB1 receptor protein increased
by 101% (p < 0.0001) (Fig. 2a, b), that of CB2 by 51%
(p < 0.05) (Fig. 2c, d) and that of COX-2 by 50%
(Fig. 2e, f ) (p < 0.05). No changes were detectable for
the relative levels of PPAR-α (Fig. 2g, h). The anti-
bodies against CB1 and COX-2 were also the only
ones to produce a reliable immunostaining in tissue
sections of rat cerebral cortex. For this reason, the
following immunohistochemical data are based exclu-
sively on the immunoreactivity that they provided.
Immunohistochemistry
In order to find a possible association between the mo-
lecular changes observed by HPLC and Western Blot
analyses and the tissue morphology, immunoreactivities
to CB1 and COX-2 were also examined in the cerebral
cortex. All markers labelled neuronal structures distrib-
uted throughout the rostro-caudal extension of the
frontal cortex (Figs 3 and 4) and the temporal-occipital
cortex (data not shown).
CB1 receptor-antibody labelled a dense to moderate
plexus of beaded fibers and a discrete number of
neuronal cell bodies distributed throughout the cortical
layers (Fig. 3). As a general rule the density of labelled
nerve terminals and fibers appeared higher in BCCAO/R
animals (Fig. 3b) than in the sham-operated ones
(Fig. 3a). By contrast, the COX-2-like immunoreactivity
appeared as intracytoplasmic granules of different dens-
ity in the perikaryon and proximal processes of neuronal
cells (Fig. 4), being intensely stained and easily detect-
able in layers II/III and V. As a general rule, the staining
intensity and density of labelled structures were higher
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in BCCAO/R (Fig. 4b) than in sham-operated rat brains
(Fig. 4a). Representative double immunostainings for
COX-2 and either glial marker Iba1 (for microglia) or
GFAP (for astrocytes), carried out in the BCCAO/R rats,
showed the absence of colocalization and demonstrated
that COX-2 immunolabelling was localized to neuronal
cell bodies (Fig. 5).
Discussion
The primary findings of this study are that BCCAO
for 30 min followed by 60 min reperfusion of the
brain is sufficient to cause molecular changes includ-
ing: i) a significant positive modulation of the eCB
system, involving the cerebral tissue and plasmatic
levels of eCBs and congeners and tissue expression of
Fig. 3 CB1-like immunoreactivity in the frontal cortex. Brain sections of sham-operated and BCCAO/R rats are shown in (a) and (b), respectively.
Panels (a) and (b) are representative of observations carried out in 6 sham-operated and 6 BCCAO/R rats. Positive nervous structures are distributed
throughout the cortical layers. m, molecular layer; wm, white matter. Scale bars: 50 μm
Fig. 4 Cyclooxygenase-2 (COX-2)-like immunoreactivity in the frontal cortex. Brain sections of sham-operated and BCCAO/R rats are shown in (a, b)
and (c, d), respectively. b, d represent a higher magnification of the microscopic fields squared in (a) and (c), respectively. Panels (a–d) are representative
of observations carried out in 6 sham-operated and 6 BCCAO/R rats. Positive cell bodies are mostly distributed in the superficial cortical layers.
m, molecular layer; wm, white matter. Scale bars: 50 μm
Quartu et al. Lipids in Health and Disease  (2017) 16:14 Page 7 of 11
the CB1 receptor; ii) a decrease of DHA tissue levels;
iii) an increase of lipoperoxide levels; iv) a parallel in-
crease of COX-2 expression in frontal cortex suggest-
ing that they are part of a physiological response to
the hypoperfusion/reperfusion insult.
Modulation of the eCB system by hypoperfusion/reperfusion
According to previous studies [12, 31, 32], our data
point out that in cerebral cortex there are basal differ-
ences in the occurrence and relative concentrations of
eCBs, the tissue content of which is increased after
BCCAO/R. This last observation is in line with studies
showing that brain focal ischemia and reperfusion
activate the eCB system by driving a combination of
biochemical adaptations of the NAE degrading and syn-
thesizing enzymes that, collectively, lead to the accumu-
lation of eCBs [12, 33]. The eCB congener PEA is an
important player in the endogenous defense against
neuroinflammation [33] and has beneficial pharmaco-
logical effects in several animal models of inflammation
[11, 33–35]. In particular, PEA may exert neuroprotective
effects by modulating the immune cells [36], activating
PPAR-alpha [23, 37] and blunting COX-2 activity [11].
Exogenous administration of PEA in an acute stroke
model is effective in reducing the infarct size [7].
Moreover, in human stroke eCBs and congeners have
been shown to become detectable during the acute
phase of an ischemic stroke where they may play a
role through multiple potential mechanisms [17].
Research into this suggested that the inhibition or
modulation of the enzymatic breakdown of PEA may
represent a complementary therapeutic approach to
counteract neuroinflammation [33].
Our data also show that after BCCAO/R a con-
comitant 38% increase of AEA could be detected in
plasma. It is difficult to speculate whether the eCB
modifications in brain tissue are directly correlated to
the observed increase in AEA plasma levels. Clinical
studies support the notion that neurological and
neuropsychiatric disorders are characterized by detect-
able changes in eCB plasma levels [17 and refs
therein]. Raise in the eCB levels in acute stroke pa-
tients have been detected by in vivo microdialysis [5]
and plasma analysis [17]. Interestingly, the increases of
AEA and PEA plasma level have been reported to show a
positive correlation with infarct volume and/or neuro-
logical disability, so that patients with higher AEA and
PEA levels had greater neurological impairment [17]. It
has been proposed that a contribution to eCB and
congener plasma levels might be due to a brain dam-
age “spill over” effect to the peripheral circulation,
the extent of which may reflect the severity of central
nervous system pathology [14, 17]. On the other
hand, it has been reported that the BCCAO modifies
the pial microvasculature and that restoration of
blood circulation in reperfusion causes a reactive
hyperaemia [4]. Whether similar changes in vascular
tone are responsible for setting off or modulating the
brain “spill over” of eCBs into systemic circulation is
an important issue to be taken into consideration. As
for the functional meaning of the increase in eCB
levels following the BCCAO/R, it can be inferred that
it contributes to neuroprotection by different path-
ways. Whether in the BCCAO/R model used in this
study the apparently concomitant raise in eCB con-
centrations and COX-2 protein levels are mutually
dependent events is an issue that remains to be clari-
fied [38].
In this study, we have also demonstrated that, after
BCCAO/R, higher concentration of eCBs are associated
with an increase of the relative levels of CB1 and CB2
receptor proteins. We may speculate that CB1 may act
synergistically to increase eCB tone, which may be crit-
ical for protection against transient hypoperfusion/reper-
fusion cerebral insult [25]. Moreover, in agreement with
previous observations [39], the extensive CB1-positive
innervation that we observed in the cerebral cortex may
Fig. 5 Double immunofluorescence for cyclooxygenase-2 (COX-2)
(a, b, e, f) and either Iba1 (c, e) or glial fibrillary acidic protein (GFAP) (d, f)
in the frontal cortex of BCCAO/R rats. Scale bars E = A, C: 25 μm; F = B,
D: 10 μm
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suggest that intrinsic local circuits may contribute to
the modulation of the reperfusion-induced tissue
challenge. It is tempting to hypothesize that the
BCCAO/R-induced increase of relative CB2 protein
levels adds to this framework, probably regulating the
production of pro-inflammatory molecules by glial
cells, through which CB2 may either prevent the
detrimental effects of neuroinflammatory reaction or
participate in adaptive changes to the brain insult
[40, 41]. As already proposed [42, 43], a parallel in-
crease of the levels of eCBs and CB1 receptors indi-
cates a sensitization of the cannabinoidergic system
that may contribute to the regulation of cellular
functions that depend upon CB1 receptor activation.
It can be suggested that, after BCCAO/R, this
sensitization modulates events such as neurotransmit-
ter release, calcium cellular influx, oxidative stress
damage, and vascular tone that appear to be crucial
in the response of cerebral tissue to the ischemia/re-
perfusion insult. Further, in light of the evidence that
eCBs may act as ligands for receptors other than CBs
[44], it is interesting that the endocannabinoid and
endovanilloid pathways have been found to antagonis-
tically interact to adjust synaptic strength of inhibi-
tory synapses [45].
Evidences for hypoperfusion/reperfusion-induced oxidative
stress
In line with our previous findings [3], the present data
indicate that the BCCAO/R causes a significant decrease
of DHA, a polyunsaturated fatty acid that is richly
endowed and avidly retained in the brain [46, 47] and
confirm that the BCCAO/R model is sufficient to perturb
tissue homeostasis by disrupting the normal DHA levels
and thus by potentially affecting the efficiency of
membrane-depending molecular mechanisms [48]. DHA
is recognized to be particularly liable to lipid peroxidation
[49] and, therefore, to be potentially apt to contribute to
the hypoperfusion/reperfusion-induced oxidative stress.
However, several lines of evidence have associated in-
creased levels of DHA with tissue protection in neuro-
inflammation [49], suggesting that DHA per se does not
increase susceptibility to oxidative stress. Data in rodents
and healthy humans support this inference, as dietary
supplementation with n-3 PUFAs does not affect lipid
peroxidation [50, 51]. By contrast, since DHA has been
shown to have a role in neuroprotection after brain hyp-
oxia and ischemia, it is relevant that recent prophylactic
and therapeutic approaches for cerebrovascular disease
take into account the pathways of brain accretion and
delivery of DHA [48, 52].
In our study, eCB changes were further characterized by
a marked increase of tissue and plasmatic concentrations
of lipoperoxides that is one of the hallmarks of the
reperfusion-induced oxidative stress [53, 54]. Lipoperox-
ides are quite unstable compounds that are capable of ex-
tending the free radical oxidative damage, and forming
proinflammatory substances [53, 54]. The increase in lipo-
peroxide levels without any evident histological alteration
of cerebral tissue is in line with previous experimental
findings on a rat model of BCCAO/R similar to ours [55].
Clinical implications
Increase of levels of lipoperoxides and a concomitant
increase of their catabolism in peroxisomes have
been shown to be directly correlated with the hypo-
perfusion/reperfusion-induced oxidative challenge in
patients undergoing carotid endoarterectomy [55]. In
particular, it is interesting that peroxisomal beta-
oxidation increased during the first 30 min of reper-
fusion only in patients having contralateral carotid
stenosis higher than 50% to decrease thereafter
within 2 h from reperfusion [55].
Several physiopathological conditions, not necessar-
ily associated with early obvious neurological signs
[56], share the occurrence of cerebral hypoperfusion
episodes for which the detection of molecular indica-
tors in the early hours may be useful in clinical
settings to prevent irreversible cerebral damage. The
question of whether plasmatic changes of AEA and
lipoperoxides could represent additional specific markers
in humans should be further investigated.
Conclusions
The present study showed that the 30/60 min BCCAO/R
procedure activates the ECS in rat and induces parallel
changes in the fatty acid tissue profile (namely decreased
levels of DHA and increased the lipoperoxides) and COX-
2 levels in the rat frontal cortex. In addition, we found that
BCCAO/R increased plasmatic levels of anandamide and
lipoperoxides. The molecular changes induced by the
BCCAO/R are evaluated on the basis of a single time
point of reperfusion and, so far, this aspect represents an
intrinsic limitation. Additional studies are warranted to
evaluate both the time course of these changes during
longer time points of reperfusion (e.g., at 6, 12 and 24 h
after BCCAO/R) and the possible effects of dietary com-
pounds in preventing BCCAO/R-induced oxidative stress.
In conclusion this study shows that BCCAO/R-in-
duced positive modulation of the ECS. As far as we
aware, this is the first study that has investigated early
changes that can be easily traced in brain tissue as well
as in plasma, and may be interpreted as indicative of the
tissue physiological response to the oxidative stress in-
duced by the BCCAO/R. The variations observed sug-
gest that the activation of the ECS and the increase of
pro-inflammatory substances are events that may be
directly correlated.
Quartu et al. Lipids in Health and Disease  (2017) 16:14 Page 9 of 11
Abbreviations
AEA, anandamide: N-arachidonoyl-ethanolamide; 2-AG: 2-arachidonoyl-
glycerol; BCCAO/R: Bilateral common carotid artery occlusion/reperfusion;
COX-2: Cyclooxygenase-2; DHA: Docosahexaenoic acid; eCBs: Endocannabinoids;
ECS: Endocannabinoid system; GAPDH: Glyceraldehyde phosphate
dehydrogenase; NAE: N-acylethanolamides; OEA: Oleoylethanolamide;
PB: Phosphate buffer; PBS: Phosphate buffered saline; PEA: Palmitoylethanolamide;
PPAR: Peroxisome-proliferator activated receptor; PUFA: Polyunsaturated fatty
acids; SDS: Sodium dodecyl sulfate; TBS-T: Tris-buffered saline-Tween 20
Aknowledgements
The study was partially supported by Fondazione Banco di Sardegna. LP was
funded with a research fellowship by the Regione Autonoma della Sardegna.
Funding
This work was supported by Grant from University of Cagliari (Progetti di
Ricerca di Interesse Dipartimentale, PRID 2015) and Regione Autonoma
della Sardegna (LP).
Availability of data and materials
The datasets obtained during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
MQ and SB conceived the study, participated in its design and coordination
and drafting, and wrote the manuscript; LP conceived and participated in
the design of the study, carried out the protein analysis, elaborated the data;
TM performed the surgery, carried out protein analysis and elaborated the
data; MPS and MB carried out the tissue sampling and performed the
statistical analysis of western blot data; SL, GC and EM, participated in the
design of the study, performed the eCB analysis and elaborated the data;
LM performed the fatty acid analysis and elaborated the data; MC gave a
critical contribution to the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 22 September 2016 Accepted: 13 December 2016
References
1. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain
injury following ischemia and reperfusion. J Appl Physiol. 1991;71:1185–95.
2. Coyle P, Panzenbeck MJ. Collateral development after carotid artery occlusion
in Fischer 344 rats. Stroke. 1990;21:316–21.
3. Quartu M, Serra MP, Boi M, Pillolla G, Melis T, Poddighe L, et al. Effect of
acute administration of Pistacia lentiscus L. essential oil on rat cerebral
cortex following transient bilateral common carotid artery occlusion.
Lipids Health Dis. 2012;11:8.
4. Lapi D, Vagnani S, Pignataro G, Esposito E, Paterni M, Colantuoni A. Rat pial
microvascular responses to transient bilateral common carotid artery occlusion
and reperfusion: quercetin’s mechanism of action. Front Physiol. 2012;3:99.
5. Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S,
et al. Release of fatty acid amides in a patient with hemispheric stroke:
a microdialysis study. Stroke. 2002;33:2112–4.
6. Melis MP, Angioni E, Carta G, Murru E, Scanu P, Spada S, et al. Characterization
of conjugated linoleic acid and its metabolites by RPHPLC with diode array
detector. Eur J Lipid Sci Technol. 2001;103:617–21.
7. Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR.
Endocannabinoids mediate neuroprotection after transient focal
cerebral ischemia. Brain Res. 2008;1240:213–20.
8. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels
in health and disease. Curr Opin Lipidol. 2008;18:129–40.
9. Di Marzo V. The endocannabinoid system: its general strategy of action,
tools for its pharmacological manipulation and potential therapeutic
exploitation. Pharmacol Res. 2009;60:77–84.
10. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory
action of endocannabinoid palmitoylethanolamide and the synthetic
cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol.
2002;135:181–7.
11. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous
fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition
of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137:413–20.
12. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia.
Curr Pharm Des. 2008;14:2347–61.
13. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF. CB2 receptor
activation attenuates microcirculatory dysfunction during cerebral ischemic/
reperfusion injury. Microvasc Res. 2009;78:86–94.
14. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in
peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Res.
2008;14:2370–42.
15. Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in
ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;
153:252–62.
16. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G. Post-ischemic brain
damage: the endocannabinoid system in the mechanisms of neuronal
death. FEBS J. 2009;276:2–12.
17. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, et al.
Possible anandamide and palmitoylethanolamide involvement in human
stroke. Lipids Health Dis. 2010;9:47.
18. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R.
Endocannabinoids and traumatic brain injury. Br J Pharmacol. 2011;163:
1402–10.
19. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, et al.
Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide,
into prostaglandin, thromboxane, and prostacyclin glycerol esters and
ethanolamides. J Biol Chem. 2002;277:44877–85.
20. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, et al.
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases
levels of endocannabinoid related molecules and produces analgesia via
peroxisome proliferator-activated receptor-alpha in a model of inflammatory
pain. Neuropharmacol. 2008;55:85–93.
21. Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons
by limiting COX-2 elevation. J Biol Chem. 2008;283:22601–11.
22. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. Substrate-selective
COX-2 inhibition as a novel strategy for therapeutic endocannabinoid
augmentation. Trends Pharmacol Sci. 2014;35:358–67.
23. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The
nuclear receptor peroxisome proliferator-activated receptor-alpha mediates
the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol.
2005;67:15–9.
24. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide
content is increased and CB1 cannabinoid receptor blockade is protective
during transient, focal cerebral ischemia. Neuroscience. 2004;129:743–50.
25. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity
of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci.
2002;22:9771–5.
26. Di Marzo V, Goparaju SK, Wang L, Liu J, Bàtkai S, Jàrai Z, et al. Leptin-regulated
endocannabinoids are involved in maintaining food intake. Nature.
2001;410:822–5.
27. Iwasaki Y, Ito S, Suzuki M, Nagahori T, Yamamoto T, Konno H. Forebrain
ischemia induced by temporary bilateral common carotid occlusion in
normotensive rats. J Neurol Sci. 1989;90:155–65.
28. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed.
Amsterdam-Boston: Elsevier Academic Press; 2007.
29. Banni S, Carta G, Contini MS, Angioni E, Deiana M, Dessi MA, et al.
Characterization of conjugated diene fatty acids in milk, dairy products,
and lamb tissues. J Nutr Biochem. 1996;7:150–5.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with
the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
31. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ,
et al. Brain regional distribution of endocannabinoids: implications for their
biosynthesis and biological function. Biochem Biophys Res Commun.
1999;256:377–80.
Quartu et al. Lipids in Health and Disease  (2017) 16:14 Page 10 of 11
32. Liedhegner ES, Sasman A, Hillard CJ. Brain region-specific changes in
N-acylethanolamine contents with time of day. J Neurochem.
2014;128:491–506.
33. Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, et al.
N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic
strategy of resolution. Mol Neurobiol. 2015;52:1034–42.
34. De Filippis D, D’Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, et
al. Levels of endocannabinoids and palmitoylethanolamide and their
pharmacological manipulation in chronic granulomatous inflammation in
rats. Pharmacol Res. 2010;61:321–8.
35. Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF.
Measurement of palmitoylethanolamide and other N-acylethanolamines
during physiological and pathological conditions. CNS Neurol Disord Drug
Targets. 2013;12:23–33.
36. Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for
palmitoylethanolamide, an anti-inflammatory and neuroprotective
lipid mediator. Mol Neurobiol. 2013;48:340–52.
37. Hansen HS. Palmitoylethanolamide and other anandamide congeners.
Proposed role in the diseased brain. Exp Neurol. 2010;224:48–55.
38. Davies BL, Arpin DJ, Volkman KG, Corr B, Reelfs H, Harbourne RT, et al.
Neurorehabilitation strategies focusing on ankle control improve mobility and
posture in persons with multiple sclerosis. J Neurol Phys Ther. 2015;39:225–32.
39. Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat
brain using antibodies to the intracellular C-terminal tail of CB. J Comp
Neurol. 2000;422:159–71.
40. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid
CB2 receptors in human brain inflammation. Br J Pharmacol. 2008;153:277–85.
41. Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in
neurodegenerative disorders and stroke/brain trauma: from preclinical
models to clinical applications. Neurotherapeutics. 2015;12:793–806.
42. Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and
CB2), their distribution, ligands and functional involvement in nervous system
structures-a short review. Pharmacol Biochem Behav. 2008;90:501–11.
43. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, et al. Elevated
levels of endocannabinoids and CB1 receptor-mediated G-protein signalling
in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry.
2005;57:480–6.
44. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al.
Levels, metabolism, and pharmacological activity of anandamide in CB(1)
cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2)
receptor-mediated actions of anandamide in mouse brain. J Neurochem.
2000;75:2434–44.
45. Lee SH, Ledri M, Tóth B, Marchionni I, Henstridge CM, Dudok B, et al.
Multiple forms of endocannabinoid and endovanilloid signaling regulate
the tonic control of GABA release. J Neurosci. 2015;35:10039–57.
46. Garcia MC, Ward G, Ma YC, Salem Jr N, Kim HY. Effect of docosahexaenoic
acid on the synthesis of phosphatidylserine in rat brain in microsomes and
C6 glioma cells. J Neurochem. 1998;70:24–30.
47. Niemoller DT, Bazan NG. Docosahexaenoic acid neurolipidomics. Prostaglandins
Other Lipid Mediat. 2010;91:85–9.
48. Mayurasakorn K, Williams JJ, Ten VS, Deckelbaum RJ. Docosahexaenoic acid:
brain accretion and roles in neuroprotection after brain hypoxia and ischemia.
Curr Opin Clin Nutr Metab Care. 2011;14:158–67.
49. Strokin M, Sergeeva M, Reiser G. Role of Ca2 + −independent phospholipaseA2
and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid
production in brain: perspectives for protection in neuroinflammation.
Int J Devl Neurosci. 2004;22:551–7.
50. Ando K, Nagata K, Yoshida R, Kikugawa K, Suzuki M. Effect of n-3
polyunsaturated fatty acid supplementation on lipid peroxidation
of rat organs. Lipids. 2000;35:401–7.
51. Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, et al.
Dietary (n-3) fatty acids reduce plasma F2 isoprostanes but not prostaglandin
F2alpha in healthy humans. J Nutr. 2006;36:1222–8.
52. Williams JJ, Mayurasakorn K, Vannucci SJ, Mastropietro C, Bazan NG, Ten VS,
et al. N-3 fatty acid rich triglyceride emulsions are neuroprotective after
cerebral hypoxic-ischemic injury in neonatal mice. PLoS One. 2013;8:2.
53. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and
disorders. Subcell Biochem. 2008;49:241–68.
54. Niki E. Lipid peroxidation: physiological levels and dual biological effects.
Free Radic Biol Med. 2009;47:469–84.
55. Yanpallewar SU, Hota D, Rai S, Kumar M, Acharya SB. Nimopidine attenuates
biochemical, behavioral and histopathological alterations induced by acute
transient and long-term bilateral common carotid occlusion in rats. Pharmacol
Res. 2004;49:143–50.
56. Banni S, Montisci R, Sanfilippo R, Finco G, Sanna D, Giordano E, et al.
Physiological response to lipid peroxidation in ischemia and reperfusion
during carotid endarterectomy. Lipids Health Dis. 2010;9:41.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Quartu et al. Lipids in Health and Disease  (2017) 16:14 Page 11 of 11
